Testing an Antibody Again in Gastric Cancer After It Stopped Working

When a cancer drug stops working, doctors sometimes wonder whether giving it a second chance, later in the disease, could still buy time. A new randomised trial put that idea to a formal test in advanced stomach cancer, and the answer is a cautious one.

Advanced stomach cancer is one of the harder problems in oncology. Once the disease has spread, treatment options narrow quickly, and each new line of therapy tends to work for a shorter time than the one before. So researchers keep looking for ways to squeeze more benefit out of the tools they already have. One of those tools is zolbetuximab, a laboratory-made antibody that attaches to a protein called claudin 18.2. This protein normally sits between healthy stomach lining cells, tucked away from the immune system, but in many gastric tumours it becomes exposed on the cell surface. That makes it a target: the antibody latches on and flags the cancer cell for destruction. In first-line treatment, combined with chemotherapy, zolbetuximab has already shown it can help selected patients whose tumours carry enough of this protein.

The question the ZELDA trial set out to answer was narrower and more unusual. It asked what happens when the drug is used a second time, in people who had received zolbetuximab before and whose cancer had progressed anyway. Re-treating with a drug that has already stopped working is not obviously sensible, but it is not absurd either. Tumours are mixtures of cells, and a therapy that fails overall may still hold back part of the disease. In some cancers, returning to an earlier drug after a break has produced modest gains. ZELDA was designed to see whether that logic holds for claudin 18.2 in the stomach.

This was a randomised phase II study, which means patients were assigned by chance to different treatment groups, and it was aimed at generating evidence rather than delivering a final verdict. Everyone enrolled had advanced gastric or gastro-oesophageal junction cancer, tumours that tested positive for claudin 18.2, and prior exposure to zolbetuximab. The trial focused on second-line treatment, the stage reached after an initial regimen has failed. Randomising patients this way matters, because it is the cleanest way to separate a real drug effect from the natural ups and downs of a serious illness and from the differences between one patient and the next.

Phase II trials of this kind are built to measure whether a treatment shows enough signal to justify a larger, more definitive study. They look at how long the disease is held in check, how many tumours shrink, and how well patients tolerate the treatment. They are rarely large enough to prove that a drug extends survival across the whole population, and they are not meant to. The honest way to read a trial like ZELDA is as a step in a longer process: a structured attempt to find out whether re-treatment deserves further investment, or whether the idea should be set aside.

The concept of returning to a previously used therapy is worth understanding, because it runs against a common intuition. Patients and families often assume that once a drug fails, it is finished. Biology is less tidy. Cancers evolve under the pressure of treatment, and the cells that survive one round are not always the same as the cells that dominate later. A target like claudin 18.2 may still be present on many tumour cells even after the disease has grown back. Whether that lingering presence translates into a clinical benefit when the antibody is given again is precisely the kind of thing that only a controlled trial can settle, rather than reasoning from the mechanism alone.

What a study like this cannot do is tell any individual whether re-treatment would help them. It works at the level of averages across a group, and it deals with a very specific situation: advanced disease, a confirmed claudin 18.2-positive tumour, and prior use of this particular antibody. It says nothing about earlier-stage cancer, about tumours that do not carry the target, or about other drugs. Nor does a phase II result establish that a treatment should enter routine practice. That decision depends on larger trials, on whether the benefit is large enough to matter to patients, and on how the side effects weigh against the gains.

For anyone living with advanced gastric cancer, or supporting someone who is, the practical value of this work is indirect. It reflects a research culture willing to test its own assumptions rather than accept them, including the assumption that a failed drug has nothing left to offer. Decisions about later lines of therapy are highly individual and belong in a conversation with an oncology team, who can weigh a person's tumour biology, previous treatments and overall health. Trials like ZELDA feed that conversation with evidence, one careful question at a time, and they matter most not for the single answer they produce but for narrowing the field of what is worth trying next.